2015-01-06 18:55:04 UTC

Vasopressor Terlipressin Helped Patients with Cirrhosis, Shock

Jan. 8, 2015

Terlipressin proved noninferior to noradrenaline as a vasopressor for patients with cirrhosis and septic shock in an open-label study that randomized 84 patients. Read more in

Terlipressin proved noninferior to noradrenaline as a vasopressor for patients with cirrhosis and septic shock in an open-label study that randomized 84 patients.

Terlipressin also seemed to provide advantages over noradrenaline by contributing to greater hemodynamic stability, improved urine output, reduced variceal bleeding, a lower risk of spontaneous bacterial peritonitis, and reduced mortality in the first 48 hours, but not at 28 days.

Read more in GI & Hepatology News.

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.